Recursion
Buying intent
18 tracked signals | Top 13 topics are below | Engineering is carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Recursion's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
7d ago
24d ago
4d ago
7d ago
17d ago
17d ago
26d ago
4d ago
26d ago
4d ago
26d ago
7d ago
26d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Recursion
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
Primary products / business lines
LinkedIn company profileRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning and AI algorithms to distill from i
Top accounts researching Recursion
names withheld on the public pageThese are companies whose own people brought up Recursion unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
- Account withheldSuki1 contacts
- Account withheldbyteXL1 contacts
- Account withheldCodegnan1 contacts
- Account withheldInformatica1 contacts
- Account withheldPwC1 contacts
- Account withheldZestIoT1 contacts
- Account withheldInformation Technology Institute (ITI)1 contacts
- Account withheldCapgemini1 contacts
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Leadership — 2 people; Engineering — 1 person; Data / Analytics — 1 person
What's been said
public posts mentioning RecursionUp to 9 public excerpts naming Recursion from the past 365 days, across LinkedIn, Reddit, X, YouTube and other public sources.
It was a real treat to be back on stage at Fierce Biotech talking investor and capital markets communication. A few things I keep coming back to during the conversation: 🔹 Tech investors and biotech investors still don't speak the same language. But they're getting closer. Tech investors wants platforms: scalable, repeatable, fast. The extreme? Push a button, cure cancer. Biotech investors wants assets and clinical conviction. The extreme? Ignore where the puck is going and dismiss what AI is genuinely changing about drug discovery. The truth as usual sits in the middle. We're not clicking drugs into existence yet. But dismissing the real evolution happening in this space is too conservative. The art is finding language that brings the majority along without alienating either side. That's the challenge for comms professionals. And it’s an exciting one. 🔹 A great pitch isn't enough anymore and that's why owned channels matter. To be clear, earned media still matters enormously, but shrinking newsrooms mean you can't rely on it alone to tell your story. Owned channels give you the space to go deeper than a headline and explain the tech and science. Increasingly, they matter for another reason: as AI-driven search reshapes how people find information, optimizing your owned content for generative engines ( #GEO ) is becoming as important as SEO once was. At Recursion , we've been invested in telling our story on platforms like #LinkedIn , #Instagram and #YouTube for exactly this reason. The audience is interested, engaged and growing; and the opportunity to tell richer stories has been rewarding. 🔹 "It's not about you." Full stop. I'll keep saying it. The best communicators obsess over their audience and keep their goals clear. If you want to build a bridge, you have to speak the language of the person on the other side. Being a strategic communications partner means helping a team understand who they're talking to and how to actually reach them. It's sometimes an uncomfortable conversation. Have it anyway. 🙏 Thanks to my fellow panelists Michael Levey ( Merck ), Victoria Fort ( Ovid Therapeutics ), Susan Hager ( Andreessen Horowitz ), and Karin Hellsvik ( Foghorn Therapeutics Inc. ) for a fun conversation.
May 2026Massive congratulations to Najat Khan, PhD! No one that knows her would be surprised and we are lucky to have her at Recursion
Nov 2025It has been fantastic working with a powerhouse like Najat Khan, PhD and I know her combination of business and technical expertise will drive Recursion forward. Under Chris Gibson's leadership, we have made incredible progress on his vision and I'm very glad he will continue to support the company as Chairman for years to come. We have had a solid 2025, achieving difficult milestones with novel technologies while also implementing a disciplined operating model and solidifying our capital position. I'm excited to be a part of all the ways we will push the industry forward in the months and years to come.
Nov 2025